4 October 2013Europe

Teva wins Netherlands Copaxone case

Teva Pharmaceutical Industries has claimed victory in a patent revocation action brought by generic drug maker Mylan in the Hague over its blockbuster Copaxone drug, used in the treatment of multiple sclerosis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

IP finance gap risks startup exodus, EUIPO warns

13 April 2026 New report finds that just 13% of IP-owning firms have sought financing through their assets, with billions in potential funding left untapped, as structural barriers persist.

Europe

Patent office fee increases: What applicants must know

13 April 2026 Europe’s latest patent fee increases are modest at the EPO but include a rare steep hike in the UK, forcing applicants to reassess filing routes, portfolio value, and long-term cost strategies, say James Bell and Yelena Morozova.

Europe

UK patent office adopts EPO standards for AI inventions

9 April 2026 In light of Emotional Perception AI, the UKIPO has rewritten the rules for “mixed inventions". Matt Jefferies and Eric McNeil of Marks & Clerk explore what this pivot means for applicants protecting their AI technology.

More features

Novo Nordisk and OpenAI strike AI deal to boost drug discovery

Court narrows Mylan’s Copaxone suit but key claims survive

IP finance gap risks startup exodus, EUIPO warns

Oracle retaliates with lawsuit to laid-off staff member’s ‘demands’

Patent office fee increases: What applicants must know

LSPN Awards USA: Meet the judges

UK patent office adopts EPO standards for AI inventions

Faegre Drinker boosts FDA regulatory practice with two senior hires

Teva wins Netherlands Copaxone case

More on this story

Editor's picks

Editor's picks

More features